# Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Canonical URL: https://biopharmsignal.com/news/ENLV/enlivex-announces-receipt-of-nasdaq-minimum-bid-price-notification
Ticker: ENLV
Company: Enlivex Therapeutics
Source: Enlivex Therapeutics
Published: 2026-05-15 16:10 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p>Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today an

## Article Body
Nes-Ziona, Israel, May  15, 2026  (GLOBE NEWSWIRE) --  Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that it has received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), stating that the  closing bid price of the Company's ordinary shares during...
## Recent Company News
- 2026-06-02 08:00 EST — [ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026](https://biopharmsignal.com/news/ENLV/enlivex-to-present-quality-longevity-model-powered-by-prediction-markets-treasury-at-proof-of-talk-2026) — Source: Enlivex Therapeutics
- 2026-06-01 08:00 EST — [Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026](https://biopharmsignal.com/news/ENLV/allocetra-shows-durable-6-month-efficacy-in-knee-osteoarthritis-phase-iia-trial-oral-presentation-at-eular-2026) — Source: Enlivex Therapeutics
- 2026-05-28 08:00 EST — [Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-holdings-valued-at-approximately-1-16-billion-rain-foundation-appoints-industry-leaders-to-advisory-board) — Source: Enlivex Therapeutics
- 2026-05-27 08:00 EST — [Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-rain-protocol-jumps-into-top-three-global-prediction-markets-in-league-table-following-100m-in-additional-liquidity) — Source: Enlivex Therapeutics
- 2026-05-18 08:00 EST — [Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis](https://biopharmsignal.com/news/ENLV/enlivex-announces-dosing-of-first-patient-in-the-united-states-as-part-of-its-phase-2b-trial-of-allocetra-in-age-related-primary-moderate-to-severe-knee-osteoarthritis) — Source: Enlivex Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-na&#239;ve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)